Search

Search Results

• Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma: A Literature Review and Our Own Experience

  Ulyana Gordeevna Koshkina, A.A. Semenova, M.Yu. Kichigina, D.N. Tupitsyna, V.O. Shpirko, A.I. Cherencova, S.F. Ramazanova, N.O. Zemlyakov, I.Z. Zavodnova, A.V. Arakelyan, G.D. Petrova, O.Yu. Baranova, G.S. Tumyan

  59-69

  01.01.2026

• Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed Mantle Cell Lymphoma Involving CNS: Two Case Reports and Literature Review

  Evgenii Olegovich Kunevich, N.N. Nemstsveridze, M.A. Mikhaleva, A.Yu. Kuvshinov, T.V. Ovchinnikova, E.V. Koryakina, S.V. Samarina, K.Yu. Krutikova, S.V. Sidorkevich, S.V. Voloshin

  184-196

  01.04.2025

• Options for Program Chemotherapy and Their Outcomes in Patients with Newly Diagnosed Mantle Cell Lymphoma Based on the Data from a Single Center

  Ulyana Gordeevna Koshkina, G.S. Tumyan, A.A. Semenova, M.Yu. Kichigina, I.Z. Zavodnova, D.N. Tupitsyna, E.V. Paramonova, A.S. Antipova, V.O. Shpirko, Yu.I. Klyuchagina, S.F. Ramazanova, A.V. Arakelyan, G.D. Petrova, O.Yu. Baranova, N.A. Kupryshina, E.A. Osmanov

  121-133

  01.04.2025

• Personalized Approach to Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Respect to Molecular Landscape: A Case Report and Literature Review

  Marat Albertovich Mingalimov, E.A. Baryakh, T.N. Tolstykh, A.V. Misyurin, L.A. Kesaeva, A.S. Mkrtchyan, A.M. Kovrigina, E.N. Misyurina, M.S. Orlova, T.S. Chudnova, D.D. Ivanova, O.L. Kochneva, S.S. Andreev, K.V. Yatskov, I.V. Samsonova, M.A. Lysenko

  177-183

  01.04.2025

• The Role of Somatic Mutations in Various Genes and the Issue of Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: A Literature Review

  Elena Andreevna Kuzmina, E.Yu. Chelysheva, B.V. Biderman, A.G. Turkina

  10-20

  01.01.2025

• Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)

  Margarita Anatolevna Gurianova, V.I. Kazey, O.A. Shukhov, E.Yu. Chelysheva, A.G. Nikiforova, P.D. Sobolev, M.S. Dolov, D.Yu. Grebenkin, A.N. Petrova, A.V. Bykova, I.S. Nemchenko, E.A. Kuzmina, L.V. Gavrilova, A.V. Kokhno, A.G. Turkina

  347-359

  01.10.2024

• Treatment Outcomes with Asciminib, the First Allosteric BCR::ABL1 Tyrosine Kinase Inhibitor, in Chronic Myeloid Leukemia Patients with Multiple Resistance to Prior Therapy

  A.G. Turkina, Elena Andreevna Kuzmina

  311-320

  09.06.2023

• KIR-Genetic Factors and Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

  Elena Vital’evna Kuzmich, I.E. Pavlova, L.N. Bubnova, S.S. Bessmeltsev

  119-127

  03.03.2023

• Ibrutinib Efficacy in First-Line Therapy of High-Risk Patients Vs. Second- and Third-Line Therapies of Resistant Chronic Lymphocytic Leukemia

  Nadezhda Viktorovna Kurkina, E.A. Repina, P.V. Volkova, A.A. Repin

  209-212

  03.03.2023

• Combination of Ibrutinib and Venetoclax in the Therapy of Chronic Lymphocytic Leukemia: A Review of the Latest Data from Clinical Studies

  A.A. Petrenko, Mariya Igorevna Kislova, E.A. Dmitrieva, E.A. Nikitin, V.V. Ptushkin

  37-45

  01.01.2023

• Gilteritinib as a New Option for the Treatment of Relapsed/Refractory Acute Myeloid Leukemias with FLT3 Gene Mutation: A Literature Review and Three Case Reports

  D.V. Motorin, L.L. Girshova, E.G. Lomaia, Yu.A. Alekseeva, A.V. Petukhov, V.V. Ivanov, E.K. Antonov, S.V. Efremova, A.I. Reshetova, E.N. Tochenaya, Aleksina Alekseevna Shatilova, E.N. Tochenaya, A.V. Petrov, T.S. Nikulina, K.V. Bogdanov, D.V. Ryzhkova, Yu.V. Mirolyubova, I.E. Prokop’ev, I.G. Budaeva

  69-79

  01.01.2023

• Asciminib in Chronic Myeloid Leukemia Patients Without Therapeutic Alternatives: Results of the MAP (Managed Access Program, NCT04360005) Trial in Russia

  A.G. Turkina, Elena Andreevna Kuzmina, E.G. Lomaia, E.V. Morozova, E.Yu. Chelysheva, O.A. Shukhov, A.N. Petrova, T.V. Chitanava, Yu.Yu. Vlasova, I.S. Nemchenko, A.V. Bykova, E.I. Sbityakova, M.A. Gurianova, N.N. Tsyba, A.V. Kokhno, E.N. Parovichnikova

  54-68

  01.01.2023

• Efficacy Predictors of the Third-Line Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase of Chronic Myeloid Leukemia: Results of a Multi-Center Study

  E.G. Lomaia, V.A. Shuvaev, Tamara Vangelevna Chitanava, Yu.D. Matvienko, I.S. Martynkevich, S.V. Voloshin, E.V. Efremova, E.S. Mileeva, M.S. Fominykh, A.E. Kersilova, E.V. Karyagina, N.V. Il’ina, N.V. Dorofeeva, N.V. Medvedeva, A.V. Klimovich, T.V. Shneider, S.A. Stepanova, N.F. Polezhaikovskaya, N.T. Siordiya, E.I. Sbityakova, N.S. Lazorko, E.N. Tochenaya, D.V. Motorin, N.A. Shnalieva, Yu.A. Alekseeva, D.B. Zammoeva, A.Yu. Zaritskey

  271-281

  01.07.2022

• Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response (READIT-2020): Background, Aim, Mai

  A.G. Turkina, Margarita Anatolevna Gurianova, E.Yu. Chelysheva, O.A. Shukhov

  54-61

  01.01.2022

• Biological Mechanisms of Sustaining Deep Molecular Response in Chronic Myeloid Leukemia Upon Withdrawal of Tyrosine Kinase Inhibitors

  Ekaterina Yurevna Chelysheva, M.A. Guryanova, A.G. Turkina

  427-435

  01.10.2021

• Treatment of Mastocytosis: A Literature Review

  Karina Maksimovna Chernavina, A.S. Orlova, E.A. Nikitin

  361-369

  01.07.2021

• Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors

  Margarita Anatolevna Guryanova, E.Yu. Chelysheva, A.G. Turkina

  118-128

  01.01.2021

• Factors for Sustaining Molecular Remission after Discontinuation of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia: Results of Non-Randomized Prospective Clinical Trial

  Oleg Aleksandrovich Shukhov, A.N. Petrova, E.Yu. Chelysheva, A.V. Bykova, I.S. Nemchenko, A.G. Turkina

  1-12

  01.01.2021

• Chronic Myeloid Leukemia: Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Tyrosine Kinase Inhibitors

  Elena Vladislavovna Morozova, Yu.Yu. Vlasova, M.V. Barabanshchikova, N.N. Mamaev, I.M. Barkhatov, A.L. Alyanskii, E.I. Darskaya, M.V. Vladovskaya, S.N. Bondarenko, I.S. Moiseev, B.V. Afanasyev

  193-198

  01.04.2020

• Diagnosis and Treatment of Clonal Myeloproliferative Neoplasms with Eosinophilia

  Irina Semenovna Nemchenko, N.N. Tsyba, A.G. Turkina, E.Yu. Chelysheva, O.A. Shukhov, A.M. Kovrigina, T.N. Obukhova

  161-169

  01.04.2020

• Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy

  L.M. Makeeva, E.I. Emelina, A.V. Bykova, Gennadii Efimovich Gendlin, G.A. Gusarova, I.G. Nikitin, E.Yu. Chelysheva, O.Yu. Vinogradova, I.E. Lazarev, E.G. Arshanskaya, A.G. Turkina

  104-111

  01.01.2020

• The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients

  Nadezhda Viktorovna Kurkina, E.A. Repina, N.N. Mashnina

  278-281

  01.07.2019

• Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)

  Ekaterina Yur’evna Chelysheva, A.G. Turkina, E.S. Polushkina, M.A. Vinogradova, R.G. Shmakov

  202-210

  01.04.2019

• Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ)

  Oleg Aleksandrovich Shukhov, A.G. Turkina, E.Yu. Chelysheva, A.V. Bykova, A.N. Petrova, G.A. Gusarova, I.S. Nemchenko, A.O. Abdullaev, T.N. Obukhova, A.B. Sudarikov

  194-201

  01.04.2019

• Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

  I.L. Davydkin, Kseniya Viktorovna Naumova, A.M. Osadchuk, I.A. Zolotovskaya, O.E. Danilova, T.Yu. Stepanova, O.V. Tereshina, L.V. Limareva, A.S. Shpigel’, T.P. Kuz’mina

  378-387

  01.10.2018

• Clinical Experience and Perspectives of Bosutinib Use in Patients with Chronic Myeloid Leukemia

  V.A. Shuvaev, Ol’ga Yur’evna Vinogradova, I.S. Martynkevich, N.V. Novitskaya, M.S. Fominykh, S.N. Tsareva, D.I. Shikhbabaeva, M.M. Pankrashkina, M.V. Chernikov, N.N. Sharkunov, I.I. Zotova, V.Yu. Udal’eva, E.V. Motyko, S.V. Voloshin

  288-294

  01.10.2018

• Epidemiology of Chronic Myeloid Leukemia in the Republic of Bashkortostan

  N.R. Ryabchikova, Guzyal’ Shagbanovna Safuanova, V.I. Nikulicheva

  349-353

  01.10.2018

• Clinical Recommendations for the Diagnosis and Treatment of Chronic Myeloid Leukemia

  Anna Grigor’evna Turkina, A.Yu. Zaritskii, V.A. Shuvaev, E.Yu. Chelysheva, E.G. Lomaia, E.V. Morozova, A.K. Golenkov, T.I. Pospelova, O.A. Shukhov, M.S. Fominykh, G.A. Gusarova, L.A. Kuz’mina, A.O. Abdullaev, I.S. Martynkevich

  294-316

  01.07.2017

• Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice

  Anna Grigor’evna Turkina, N.V. Novitskaya, A.K. Golenkov, V.A. Shuvaev, L.I. Napso, I.V. Krylova, A.M. Savrilova, G.Sh. Safuanova, A.V. Korobkin, T.Yu. Klitochenko, E.V. Burnasheva, E.V. Vasil’ev, O.M. Senderova, E.Yu. Fedorova, L.M. Yalunina, E.K. Nekhai, G.B. Kuchma, A.S. Lyamkina, N.G. Shchedrova

  390-401

  01.07.2017

• Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors

  Galina Anatol’evna Gusarova, A.G. Turkina

  474-484

  01.10.2016

• Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy

  K.M. Abdulkadyrov, Vasilii Anatol’evich Shuvaev, I.S. Martynkevich, M.S. Fominykh, N.A. Potikhonova, I.I. Zotova, V.Yu. Udal’eva, R.A. Golovchenko, N.V. Shakhvorostova, D.I. Shikhbabaeva, M.N. Zenina, S.A. Tiranova, S.A. Kudryashova, L.S. Martynenko, M.P. Ivanova, N.Yu. Tsybakova, E.V. Petrova, L.B. Polushkina, E.V. Kleina

  54-60

  01.01.2016

• Second Generation Tyrosine Kinase Inhibitors and Their Toxicity in Treatment of Patients in Chronic Phase of Chronic Myeloid Leukemia

  N.S. Lazorko, Elza Galaktionovna Lomaia, E.G. Romanova, E.I. Sbityakova, E.R. Machyulaitene, P.A. Butylin, A.Yu. Zaritskii

  302-308

  01.07.2015

• Mixed-Phenotype Acute Leukemia: Clinical and Laboratory Features, and Prognosis

  A.S. Antipova, Ol’ga Yur’evna Baranova, M.A. Frenkel’, N.N. Tupitsyn, N.A. Kupryshina, T.N. Obukhova, A.D. Shirin

  136-150

  01.04.2015

• First Line Treatment Choice for Chronic Myelogenous Leukemia: Modeling of Clinical and Economic Factors

  Vasilii Anatol’evich Shuvaev, K.M. Abdulkadyrov, I.S. Martynkevich, M.S. Fominykh

  78–83

  01.01.2015

• B-Cell Receptor Signaling Pathway: Mechanisms and Inhibitors

  E.A. Nikitin

  251-263

  01.07.2014

• Imatinib Generics: Myths and Reality (Literature Review and Our Experience)

  K.M. Abdulkadyrov, V.A. Shuvaev, M.S. Fominykh

  311-316

  01.07.2014

• Role of tyrosine-kinase inhibitor selectivity in development of adverse effects during treatment of chronic myeloid leukemia

  A.A. Zeifman, E.Yu. Chelysheva, A.G. Tukrina, G.G. Chilov

  16-27

  01.01.2014

• Current best options for first line treatment of chronic phase chronic myeloid leukemia

  R. Hehlmann, S. Saußele

  9-15

  01.01.2014

• The problem of adherence to therapy in chronic myeloid leukemia: understanding the patient and making a decision

  E.Yu. Chelysheva, A.V. Galaktionova, A.G. Turkina

  157-165

  01.04.2013

• Cardiovascular complications of chronic myeloid leukemia treated with tyrosine kinase inhibitors

  G.E. Gendlin, L.M. Makeeva, E.I. Emelina, K.V. Shuikova, G.I. Storozhakov

  78-84

  01.01.2013